🇺🇸 FDA
Pipeline program

,4-diaminopyridine

199/11963

Phase 3 small_molecule completed

Quick answer

,4-diaminopyridine for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials